Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
The summary for the Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed): Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.
Federal Grant Title: | Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education, Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-25-075 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.394 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | October 14th, 2026 |
Original Application Deadline: | October 14th, 2026 |
Posted Date: | October 15th, 2024 |
Creation Date: | October 15th, 2024 |
Archive Date: | November 19th, 2026 |
Total Program Funding: | |
Maximum Federal Grant Award: | $250,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | October 15th, 2024 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- https://grants.nih.gov/grants/guide/pa-files/PAR-25-075.html
- Grant Announcement Contact
- NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
- • Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Tria...
- • Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Tria...
- • Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (...
- • Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
- • Image-Guided Cancer Interventions (STTR [R41/R42])
- • An SBIR Initiative for Image-Guided Cancer Interventions (R43/R44)
- • In Vivo Cancer Imaging Exploratory/Developmental Grants
- More Grants from the National Institutes of Health
- • Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
- • Alcohol Health Services Research (R01 Clinical Trial Optional)
- • Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
- • Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Re...
- • Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the...